Fairman Group
GSK icon

Fairman Group’s GSK GSK Stock Holding History

Fairman Group’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$972 Hold
20
– – ﹤0.01% 300
2026
Q2 		$1.06K Hold
20
– – ﹤0.01% 304
2026
Q1 		$1.11K Hold
20
– – ﹤0.01% 294
2025
Q4 		$989 Hold
20
– – ﹤0.01% 302
2025
Q3 		$872 Hold
20
– – ﹤0.01% 245
2025
Q2 		$777 Hold
20
– – ﹤0.01% 228
2025
Q1 		$3.42K Sell
20
-80
-80% -$2.93K ﹤0.01% 184
2024
Q4 		$3.42K Hold
100
– – ﹤0.01% 201
2024
Q3 		$4.13K Hold
100
– – ﹤0.01% 215
2024
Q2 		$3.89K Hold
100
– – ﹤0.01% 215
2024
Q1 		$4.33K Hold
100
– – ﹤0.01% 203
2023
Q4 		$3.74K Buy
+100
New +$3.59K ﹤0.01% 212

Other funds holding GSK

Mondrian Investment Partners
Mondrian Investment Partners London, United Kingdom $5.39B AUM 14.53% 1-Year Est. Return
Equity Investment Corp
Equity Investment Corp Atlanta, Georgia $5.3B AUM 8.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Miller Howard Investments
Miller Howard Investments Kingston, New York $3.72B AUM 18.2% 1-Year Est. Return
BI Asset Management Fondsmaeglerselskab
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return
Douglas Lane & Associates
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Welch & Forbes
Welch & Forbes Boston, Massachusetts $8.34B AUM 13.98% 1-Year Est. Return
ABC Arbitrage
ABC Arbitrage Paris, France $1.02B AUM 30.46% 1-Year Est. Return
Foster Victor Wealth Advisors
Foster Victor Wealth Advisors Greenville, South Carolina $2.02B AUM 20.94% 1-Year Est. Return

Fairman Group's GSK Position: Q3 2026 in Review

Fairman Group held its GSK (GSK) position steady in Q3 2026 at 20 shares worth $972. The position accounts for ﹤0.01% of the portfolio, ranked #300.

Fairman Group first reported a position in GSK in Q4 2023 and has held it in 12 quarters since. The position peaked at $4.33K in Q1 2024. 483 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

  • Fairman Group held 20 shares of GSK worth $972 as of Q3 2026.
  • Fairman Group left its GSK share count unchanged in Q3 2026.
  • GSK made up ﹤0.01% of Fairman Group's portfolio in Q3 2026, its #300 holding.
  • Fairman Group first reported a position in GSK in Q4 2023 and has held it in 12 quarters since.
  • Fairman Group's GSK position peaked at $4.33K in Q1 2024.
  • 483 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on Fairman Group's 13F filing for Q3 2026, filed 26 Oct 2026.